Hepatocellular carcinoma and liver metastases

Clinical data on a new dual-lumen catheter kit for surgical sealant infusion to prevent perihepatic bleeding and dissemination of cancer cells following biopsy and loco-regional treatments

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: RFA is a safe and effective procedure for treating unresectable primary or secondary liver malignancies, but it is not without complications. The most common reported complications include abdominal hemorrhage, bile leakage, biloma formation, hepatic abscesses, and neoplastic seeding. The aim of this study is to evaluate the feasibility of percutaneous use of surgical sealant with a new coaxial bilumen catheter, to prevent the perihepatic bleeding and dissemination of cancer cells through the needle-electrode (neoplastic seeding) or along the needle track. Methods: We designed a novel dual-lumen catheter to facilitate the optimal application of fibrin sealant after diagnostic and therapeutic percutaneous procedures. Percutaneous RFA has been performed using mask ventilation or neuroleptanalgesia. The main aims of this study, after the ablation procedure, in the treatment of unresectable liver cancer were to prevent major adverse events: a) the perihepatic bleeding; b) dissemination of cancer cells through the needle-electrode and or needle track. Results: A total of 181 patients were evaluated for this study at National Cancer Institute of Naples from January 2012 to January 2014. The association of blood loss (1 g/dl =1 g/dl) with age, gender, histological diagnosis were analyzed. No statistical significance was observed between bleeding and age (p∈=∈0.840), gender (p∈=∈0.607) and histological diagnosis (p∈=∈0,571), respectively. Conclusions: This study demonstrated that fibrin sealant or other surgical sealant injection, after any locoregional procedure such as biopsy or ablation, could make adverse events even more rare.

Original languageEnglish
Article number11
JournalInfectious Agents and Cancer
Volume10
Issue number1
DOIs
Publication statusPublished - Apr 10 2015

Fingerprint

Hepatocellular Carcinoma
Catheters
Needles
Hemorrhage
Neoplasm Metastasis
Biopsy
Liver
Fibrin Tissue Adhesive
Neoplasms
Electrodes
Neuroleptanalgesia
Therapeutics
Liver Abscess
National Cancer Institute (U.S.)
Liver Neoplasms
Masks
Bile
Injections

Keywords

  • Dual lumen catheter
  • Hepatocarcinoma
  • Liver metastases
  • Locoregional treatments
  • Sealant

ASJC Scopus subject areas

  • Infectious Diseases
  • Oncology
  • Epidemiology
  • Cancer Research

Cite this

@article{445427f6a287408dba494f05b0413412,
title = "Hepatocellular carcinoma and liver metastases: Clinical data on a new dual-lumen catheter kit for surgical sealant infusion to prevent perihepatic bleeding and dissemination of cancer cells following biopsy and loco-regional treatments",
abstract = "Background: RFA is a safe and effective procedure for treating unresectable primary or secondary liver malignancies, but it is not without complications. The most common reported complications include abdominal hemorrhage, bile leakage, biloma formation, hepatic abscesses, and neoplastic seeding. The aim of this study is to evaluate the feasibility of percutaneous use of surgical sealant with a new coaxial bilumen catheter, to prevent the perihepatic bleeding and dissemination of cancer cells through the needle-electrode (neoplastic seeding) or along the needle track. Methods: We designed a novel dual-lumen catheter to facilitate the optimal application of fibrin sealant after diagnostic and therapeutic percutaneous procedures. Percutaneous RFA has been performed using mask ventilation or neuroleptanalgesia. The main aims of this study, after the ablation procedure, in the treatment of unresectable liver cancer were to prevent major adverse events: a) the perihepatic bleeding; b) dissemination of cancer cells through the needle-electrode and or needle track. Results: A total of 181 patients were evaluated for this study at National Cancer Institute of Naples from January 2012 to January 2014. The association of blood loss (1 g/dl =1 g/dl) with age, gender, histological diagnosis were analyzed. No statistical significance was observed between bleeding and age (p∈=∈0.840), gender (p∈=∈0.607) and histological diagnosis (p∈=∈0,571), respectively. Conclusions: This study demonstrated that fibrin sealant or other surgical sealant injection, after any locoregional procedure such as biopsy or ablation, could make adverse events even more rare.",
keywords = "Dual lumen catheter, Hepatocarcinoma, Liver metastases, Locoregional treatments, Sealant",
author = "Francesco Izzo and Raffaele Palaia and Vittorio Albino and Alfonso Amore and {Di Giacomo}, Raimondo and Mauro Piccirillo and Maddalena Leongito and Aurelio Nasto and Vincenza Granata and Antonella Petrillo and Secondo Lastoria",
year = "2015",
month = "4",
day = "10",
doi = "10.1186/s13027-015-0006-0",
language = "English",
volume = "10",
journal = "Infectious Agents and Cancer",
issn = "1750-9378",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Hepatocellular carcinoma and liver metastases

T2 - Clinical data on a new dual-lumen catheter kit for surgical sealant infusion to prevent perihepatic bleeding and dissemination of cancer cells following biopsy and loco-regional treatments

AU - Izzo, Francesco

AU - Palaia, Raffaele

AU - Albino, Vittorio

AU - Amore, Alfonso

AU - Di Giacomo, Raimondo

AU - Piccirillo, Mauro

AU - Leongito, Maddalena

AU - Nasto, Aurelio

AU - Granata, Vincenza

AU - Petrillo, Antonella

AU - Lastoria, Secondo

PY - 2015/4/10

Y1 - 2015/4/10

N2 - Background: RFA is a safe and effective procedure for treating unresectable primary or secondary liver malignancies, but it is not without complications. The most common reported complications include abdominal hemorrhage, bile leakage, biloma formation, hepatic abscesses, and neoplastic seeding. The aim of this study is to evaluate the feasibility of percutaneous use of surgical sealant with a new coaxial bilumen catheter, to prevent the perihepatic bleeding and dissemination of cancer cells through the needle-electrode (neoplastic seeding) or along the needle track. Methods: We designed a novel dual-lumen catheter to facilitate the optimal application of fibrin sealant after diagnostic and therapeutic percutaneous procedures. Percutaneous RFA has been performed using mask ventilation or neuroleptanalgesia. The main aims of this study, after the ablation procedure, in the treatment of unresectable liver cancer were to prevent major adverse events: a) the perihepatic bleeding; b) dissemination of cancer cells through the needle-electrode and or needle track. Results: A total of 181 patients were evaluated for this study at National Cancer Institute of Naples from January 2012 to January 2014. The association of blood loss (1 g/dl =1 g/dl) with age, gender, histological diagnosis were analyzed. No statistical significance was observed between bleeding and age (p∈=∈0.840), gender (p∈=∈0.607) and histological diagnosis (p∈=∈0,571), respectively. Conclusions: This study demonstrated that fibrin sealant or other surgical sealant injection, after any locoregional procedure such as biopsy or ablation, could make adverse events even more rare.

AB - Background: RFA is a safe and effective procedure for treating unresectable primary or secondary liver malignancies, but it is not without complications. The most common reported complications include abdominal hemorrhage, bile leakage, biloma formation, hepatic abscesses, and neoplastic seeding. The aim of this study is to evaluate the feasibility of percutaneous use of surgical sealant with a new coaxial bilumen catheter, to prevent the perihepatic bleeding and dissemination of cancer cells through the needle-electrode (neoplastic seeding) or along the needle track. Methods: We designed a novel dual-lumen catheter to facilitate the optimal application of fibrin sealant after diagnostic and therapeutic percutaneous procedures. Percutaneous RFA has been performed using mask ventilation or neuroleptanalgesia. The main aims of this study, after the ablation procedure, in the treatment of unresectable liver cancer were to prevent major adverse events: a) the perihepatic bleeding; b) dissemination of cancer cells through the needle-electrode and or needle track. Results: A total of 181 patients were evaluated for this study at National Cancer Institute of Naples from January 2012 to January 2014. The association of blood loss (1 g/dl =1 g/dl) with age, gender, histological diagnosis were analyzed. No statistical significance was observed between bleeding and age (p∈=∈0.840), gender (p∈=∈0.607) and histological diagnosis (p∈=∈0,571), respectively. Conclusions: This study demonstrated that fibrin sealant or other surgical sealant injection, after any locoregional procedure such as biopsy or ablation, could make adverse events even more rare.

KW - Dual lumen catheter

KW - Hepatocarcinoma

KW - Liver metastases

KW - Locoregional treatments

KW - Sealant

UR - http://www.scopus.com/inward/record.url?scp=84927913917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927913917&partnerID=8YFLogxK

U2 - 10.1186/s13027-015-0006-0

DO - 10.1186/s13027-015-0006-0

M3 - Article

VL - 10

JO - Infectious Agents and Cancer

JF - Infectious Agents and Cancer

SN - 1750-9378

IS - 1

M1 - 11

ER -